Abstract
Controlled human malaria infection (CHMI) provides a highly informative means to investigate host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new drugs and vaccines. However, unlike Plasmodium falciparum, well-characterized P. vivax parasites that are safe and suitable for use in modern CHMI models are limited. Here, two healthy malaria-naïve UK adults with universal donor blood group were safely infected with a clone of P. vivax from Thailand by mosquito-bite CHMI. Parasitemia developed in both volunteers and, prior to treatment, each volunteer donated blood to produce a cryopreserved stabilate of infected red blood cells. Following stringent safety screening, the parasite stabilate from one of these donors (“PvW1”) was thawed and used to inoculate six healthy malaria-naïve UK adults by blood-stage CHMI, at three different dilutions. Parasitemia developed in all volunteers, who were then successfully drug treated. PvW1 parasite DNA was isolated and sequenced to produce a high quality genome assembly by using a hybrid assembly method. We analysed leading vaccine candidate antigens and multigene families, including the Vivax interspersed repeat (VIR) genes of which we identified 1145 in the PvW1 genome. Our genomic analysis will guide future assessment of candidate vaccines and drugs, as well as experimental medicine studies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03377296 and NCT03797989
Funding Statement
This work was funded in part by the European Union Horizon 2020 research and innovation programme under grant agreement 733073 for MultiViVax; the UK Medical Research Council (MRC) Confidence in Concept Scheme at the University of Oxford [MC_PC_16056]; and by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). No third party funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK NHS Research Ethics Service (Oxfordshire Research Ethics Committee A, Ref 17/SC/0389); and UK NHS Research Ethics Service (South Central Hampshire A Research Ethics Committee), Ref 18/SC/0577.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Requests for materials should be addressed to the corresponding authors. PvW1 genomic assembly and annotation data can be found at: ftp://ngs.sanger.ac.uk/scratch/project/pathogens/ea10/pvivax/renamed_scaffolds/
ftp://ngs.sanger.ac.uk/scratch/project/pathogens/ea10/pvivax/renamed_scaffolds/
